NOVOB N Stock Overview Engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. More details
Rewards Risk Analysis See All Risk Checks Capture your thoughts, links and company narrative
Novo Nordisk A/S Competitors Price History & Performance
Summary of share price highs, lows and changes for Novo Nordisk Historical stock prices Current Share Price DKK 1,762.64 52 Week High DKK 2,708.33 52 Week Low DKK 1,670.00 Beta 0.20 1 Month Change 5.55% 3 Month Change -21.60% 1 Year Change n/a 3 Year Change 74.12% 5 Year Change n/a Change since IPO 75.89%
Recent News & Updates FDA Approves Novo Nordisk's Ozempic® as the Only GLP-1 RA to Reduce the Risk of Propose Kidney Disease and Cardiovascular death in Adults with Type 2 Diabetes and Chronic Kidney Disease Jan 29
Levi & Korsinsky, LLP Files A Complaint to Recover Losses Suffered by Purchasers of Novo Nordisk A/S Securities Jan 25 Novo Nordisk Successfully Completes Phase 1b/2a Trial with Subcutaneous Amycretin in People with Overweight or Obesity Jan 24
Novo Nordisk Announces Headline Results from STEP UP Jan 17
Novo Nordisk Announces FDA Approves Alhemo® Injection as Once-Daily Prophylactic Treatment to Prevent or Reduce the Frequency of Bleeding Episodes for Adults and Children 12 Years of Age and Older with Hemophilia A or B with Inhibitors Dec 22 Novo Nordisk A/S Files for A Label Expansion in the Us See more updates FDA Approves Novo Nordisk's Ozempic® as the Only GLP-1 RA to Reduce the Risk of Propose Kidney Disease and Cardiovascular death in Adults with Type 2 Diabetes and Chronic Kidney Disease Jan 29
Levi & Korsinsky, LLP Files A Complaint to Recover Losses Suffered by Purchasers of Novo Nordisk A/S Securities Jan 25 Novo Nordisk Successfully Completes Phase 1b/2a Trial with Subcutaneous Amycretin in People with Overweight or Obesity Jan 24
Novo Nordisk Announces Headline Results from STEP UP Jan 17
Novo Nordisk Announces FDA Approves Alhemo® Injection as Once-Daily Prophylactic Treatment to Prevent or Reduce the Frequency of Bleeding Episodes for Adults and Children 12 Years of Age and Older with Hemophilia A or B with Inhibitors Dec 22 Novo Nordisk A/S Files for A Label Expansion in the Us Evotec SE Announces First Projects for LAB eN2 Drug Discovery Accelerator with Novo Nordisk Dec 11
Frantz Law Group Files Oceanside Unified School District Lawsuit Against Eli Lily, Novo Nordisk, Sanofi, Express Scripts, CVS Caremark, and Optum RX for Insulin Pricing Scheme Nov 21
Novo Nordisk A/S to Report Q2, 2025 Results on Aug 06, 2025
Novo Nordisk A/S Provides Earnings Guidance for 2024 Nov 07
Third quarter 2024 earnings released: EPS: kr.6.13 (vs kr.5.02 in 3Q 2023) Nov 07
Novo Nordisk A/S Announces Results from Part 1 of the Ongoing ESSence Trial Nov 02 Novo Nordisk A/S Announces Monlunabant Phase 2A Trial in Obesity Successfully Completed Sep 20
Aragen Life Sciences Reportedly Plans to Dilute About 10% Stake Sep 18
Employee Representative Director recently sold Mex$21m worth of stock Aug 15
Second quarter 2024 earnings released: EPS: kr.4.50 (vs kr.4.33 in 2Q 2023) Aug 08 Novo Nordisk A/S Decides to Pay Interim Dividend for 2024, Payable on 19 August 2024 for A and B Shares and 26 August 2024 for ADRs European Regulatory Authority Adopts A Positive Opinion for an Update of the Wegovy® Label to Reflect Risk Reduction of Major Adverse Cardiovascular Events Jul 26
Novo Nordisk Receives Complete Response Letter in the US for Once-Weekly Basal Insulin Icodec Jul 11
Investor sentiment improves as stock rises 18% Jun 10 Novo Nordisk Announces Wegovy (Semaglutide Injection) Available in Canada Mankind Reportedly Joins Race for Healthium Medtech Mar 30
Novo Nordisk A/S (CPSE:NOVO B) agreed to acquire Cardior Pharmaceuticals GmbH from EQT Life Sciences and others for €1.03 billion. Mar 25
Novo Nordisk Announces Awiqli Recommends for Approval for the Treatment of Diabetes by the European Regulatory Authorities Mar 23
Final dividend of kr.6.40 announced Mar 17 Novo Nordisk Announces US Food and Drug Administration Approves Wegovy® Based on A Supplemental New Drug Application for the Indication of Reducing Risk of Major Dose Cardiovascular Events
President recently sold Mex$359m worth of stock Feb 14
Novo Nordisk A/S Proposes Final Dividend for the Year 2023 Feb 02 Novo Nordisk A/S Proposes Final Dividend for the Year 2023 Novo Nordisk A/S (CPSE:NOVO B) announces an Equity Buyback for DKK 20,000 million worth of its shares. Jan 31
Novo Nordisk A/S Announces Topline Results from the Combine 3 Phase 3A Trial of Once-Weekly IcoSema Jan 09
Insider recently sold Mex$26m worth of stock Nov 06
Insider recently sold Mex$26m worth of stock Nov 05 Novo Nordisk A/S to Report First Half, 2024 Results on Aug 07, 2024
Third quarter 2023 earnings released Nov 03
Novo Nordisk Revises Earnings Guidance for the Year 2023 Oct 14 Novo Nordisk to Stop the Once-Weekly Injectable Semaglutide Kidney Outcomes Trial, Flow, Based on Interim Analysis Oct 11
Novo Nordisk A/S (CPSE:NOVO B) acquired Embark Biotech ApS for approximately €470 million. Aug 31 Novo Nordisk A/S (CPSE:NOVO B) agreed to acquire Inversago Pharma Inc. from Genesys Capital Partners Inc., Accel-Rx, Tarnagulla Ventures Pty. Ltd., Fonds de solidarité FTQ, adMare BioInnovations and others for $1 billion. Aug 11
Shareholder Returns NOVOB N MX Pharmaceuticals MX Market 7D 3.0% 0.8% 0.8% 1Y n/a -19.2% -12.3%
See full shareholder returns
Return vs Market: Insufficient data to determine how NOVOB N performed against the MX Market .
Price Volatility Is NOVOB N's price volatile compared to industry and market? NOVOB N volatility NOVOB N Average Weekly Movement n/a Pharmaceuticals Industry Average Movement 5.8% Market Average Movement 4.0% 10% most volatile stocks in MX Market 6.8% 10% least volatile stocks in MX Market 2.7%
Stable Share Price: NOVOB N's share price has been volatile over the past 3 months compared to the MX market.
Volatility Over Time: Insufficient data to determine NOVOB N's volatility change over the past year.
About the Company Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease. The Diabetes and Obesity care segment provides products for diabetes, obesity, cardiovascular, and other emerging therapy areas.
Show more Novo Nordisk A/S Fundamentals Summary How do Novo Nordisk's earnings and revenue compare to its market cap? NOVOB N fundamental statistics Market cap Mex$7.71t Earnings (TTM ) Mex$272.34b Revenue (TTM ) Mex$777.98b
Earnings & Revenue Key profitability statistics from the latest earnings report (TTM) NOVOB N income statement (TTM ) Revenue DKK 270.58b Cost of Revenue DKK 41.51b Gross Profit DKK 229.07b Other Expenses DKK 134.35b Earnings DKK 94.72b
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
Feb 05, 2025
Earnings per share (EPS) 21.34 Gross Margin 84.66% Net Profit Margin 35.01% Debt/Equity Ratio 47.3%
How did NOVOB N perform over the long term?
See historical performance and comparison Dividends
1.6% Current Dividend Yield
Company Analysis and Financial Data Status Data Last Updated (UTC time) Company Analysis 2025/01/31 14:25 End of Day Share Price 2025/01/28 00:00 Earnings 2024/09/30 Annual Earnings 2023/12/31
Data Sources The data used in our company analysis is from S&P Global Market Intelligence LLC . The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package Data Timeframe Example US Source * Company Financials 10 years Income statement Cash flow statement Balance sheet Analyst Consensus Estimates +3 years Forecast financials Analyst price targets Market Prices 30 years Stock prices Dividends, Splits and Actions Ownership 10 years Top shareholders Insider trading Management 10 years Leadership team Board of directors Key Developments 10 years
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here .
Analysis Model and Snowflake Details of the analysis model used to generate this report is available on our Github page , we also have guides on how to use our reports and tutorials on Youtube .
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources Novo Nordisk A/S is covered by 71 analysts. 23 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst Institution null null ABG Sundal Collier Kamla Singh AlphaValue Gerhard Schwarz Baader Helvea Equity Research
Show 68 more analysts 